The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer

Johansen, Julia S.; Calatayud, Dan; Albieri, Vanna; Schultz, Nicolai Aagaard; Dehlendorff, Christian; Werner, Jens; Jensen, Benny Vittrup; Pfeiffer, Per; Bojesen, Stig E.; Giese, Nathalia A.; Nielsen, Kaspar René; Nielsen, Svend Erik; Yilmaz, Mette Karen; Holländer, Niels Henrik; Andersen, Klaus K.

doi:10.1002/ijc.30291

Cited by 41 publications

(47 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The levels of miR-10b, -20a, -21, -30c, -106b, -181a, -483, -20, -let7a, and -122 were assayed in exosomes and plasma, since these miRs have either been implicated in PDAC or in modulation of cancer cell proliferation and migration [24–26,35–41]. Exosomal miR-10b, -20a, -21, -30c, -106b, and -181a were present at high levels in PDAC and were low in the CP and normal samples, whereas exosomal miR-let7a (which is also known as let7a or let-7a) and miR-122 were lower in PDAC samples by comparison with either normal or CP samples, while miR-483 levels were similar in all three groups (Table 6 and Fig.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer

et al. 2017

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that often presents clinically at an advanced stage and that may be confused with chronic pancreatitis (CP). Conversely, CP may be misdiagnosed as PDAC leading to unwarranted pancreas resection. Therefore, early PDAC diagnosis and clear differentiation between PDAC and CP are crucial for improved care. Exosomes are circulating micro-vesicles whose components can serve as cancer biomarkers. We compared exosomal glypican-1 (GPC1) and microRNA levels in normal control subjects and in patients with PDAC and CP. We report that exosomal GPC1 is not diagnostic for PDAC, whereas high exosomal levels of microRNA-10b, (miR-10b), miR-21, miR-30c, and miR-181a and low miR-let7a readily differentiate PDAC from normal control and CP samples. By contrast with GPC1, elevated exosomal miR levels decreased to normal values within 24 h following PDAC resection. All 29 PDAC cases exhibited significantly elevated exosomal miR-10b and miR-30c levels, whereas 8 cases had normal or slightly increased CA 19-9 levels. Thus, our exosomal miR signature is superior to exosomal GPC1 or plasma CA 19-9 levels in establishing a diagnosis of PDAC and differentiating between PDAC and CP.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Numerous miRs are overexpressed in PDAC, including miR-10b, -20a, -21, -30c, -106b, -196a, -196b, -203, -155, -205, -210, -221, -222, -223, -486, -744, and 17-5p [24–26,35–41]. Some of these miRs are present at high levels in the plasma and serum of patients with PDAC [26,41].…”

Section: Discussionmentioning

confidence: 99%

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Apart from autoimmune antibodies, other novel markers including serum micro RNAs (miRNAs) signature have been reported to play a role in differentiating pancreatic carcinoma from AIP with high accuracy [26, 27]. MiRNA are endogenous small non-coding RNAs consisting of 19–25 nucleotides, which can interfere with gene transcription and/or translation, thus modulate the targeted gene expression[28].…”

Section: Discussionmentioning

confidence: 99%

“…miR-483), miR-155, miR-21, miR-34 and so on[28]. They not only provide for novel therapeutic options for pancreatic malignancy treatment, also the chance to aid in early diagnosis, disease monitoring and prognostic analysis[27, 29]. Recently, Manabu Akamatsu and his colleagues reported that four MAKP-associated miRNAs, miR-7, miR-34a, miR-181d, and miR-193b can be candidate biomarkers to differentiate pancreatic malignancy from AIP [30].…”

Section: Discussionmentioning

confidence: 99%

“…In recent work of Johansen and his colleagues, they analysed serum level of 34 miRNAs in patients with pancreatic cancer, chronic pancreatitis and healthy controls and developed a diagnostic panels based on 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and miR-483.5p) to distinguish pancreatic cancer from pancreatitis. When combined with serum CA 19–9, the highest AUC reached 0.94 (0.90–0.97) [27]. In conclusion, MicroRNAs regulate expression of more than 60% of all mammalian protein -coding genes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin

Yan

Chen

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Autoimmune pancreatitis (AIP) is a special type of chronic pancreatitis, which may be misdiagnosed as pancreatic carcinoma. This study aims to verify new biomarkers for AIP and propose a serological pattern to differentiate AIP from pancreatic adenocarcinoma with routinely performed tests. In this study, data of serum samples were collected and compared between 25 patients with AIP and 100 patients with pancreatic carcinoma. Receiver operating characteristic analysis and logistic regression was performed to evaluate the diagnostic effect of serum parameters in differentiating AIP from pancreatic carcinoma alone or in combination. Among several serum markers observed in the two groups, carbohydrate antigen 19–9 (Ca19-9), globulin, eosinophils and hemoglobin were selected as the independent markers. Serum levels of Globulin, Eosinophil percentage in AIP group were significantly higher than in pancreatic cancer group (P<0.05), while hemoglobin and tumor marker CA19-9 levels were lower (P <0.05). The combination of these markers identified patients with AIP with 92% sensitivity and 79% specificity, which indicated relatively high diagnostic value. Elevated serum eosinophils, globulin, together with decreased hemoglobin level can be used as a preoperative indicator for AIP and can help to initiate diagnosis of AIP in time.

show abstract

Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis

Guo

Qin

Liu

et al. 2021

Clinical & Translational Med

View full text Add to dashboard Cite

Background The differential diagnosis of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP) is clinically challenging due to a lack of minimally invasive diagnosis methods. MicroRNAs (miRNAs) derived from small extracellular vesicles (EVs) in the blood have been reported as a promising diagnosis biomarker for various types of cancer. However, blood small EV miRNA signatures and their diagnostic value to differentiate between PDAC and CP remain to be determined. Methods In this study, 107 patients with PDAC or CP were recruited, and 90 patients were finally enrolled for a training cohort ( n = 48) and test cohort ( n = 42). Small RNA sequencing was used to assess the expression of blood small EV miRNAs in these patients. Results The linear model from the differentially expressed blood small EV miR‐95‐3p divided by miR‐26b‐5p showed an average sensitivity of 84.1% and an average specificity of 96.6% to identify PDAC from CP in the training cohort and the test cohort, respectively. When the model was combined with serum carbohydrate antigen 19‐9 (CA19‐9), the average sensitivity increased to 96.5%, and the average specificity remained at 96.4% of both cohorts, which demonstrated the best performance of all the published biomarkers for distinguishing between PDAC and CP. The causal analysis performed using the Bayesian network demonstrated that miR‐95‐3p was associated with a “consequence” of “cancer” and miR‐26b‐5p as a “cause” of “pancreatitis.” A subgroup analysis revealed that blood small EV miR‐335‐5p/miR‐340‐5p could predict metastases in both cohorts and was associated with an overall survival ( p = 0.020). Conclusions This study indicated that blood small EV miR‐95‐3p/miR‐26b‐5p and its combination with serum levels of CA19‐9 could separate PDAC from CP, and miR‐335‐5p/miR‐340‐5p was identified to associate with PDAC metastasis and poor prognosis. These results suggested the potentiality of blood small EV miRNAs as differential diagnosis and metastases biomarkers of PDAC.

show abstract

The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer

Cited by 41 publications

References 42 publications

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer

Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin

Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis

Contact Info

Product

Resources

About